Ok so what we have so far is the following:
-------------------------------------
Hi Tom,
Hope you are well.
Ive had discussions with a group of investors and instead of bombarding you with questions of a similar nature we have decided to compile a list of questions from all of us for you to hopefully asisst us with (we will post the answers on Hotcopper so all investors apart of forming this list get there answers satisfied).
Questions:
About Announcement
1. Why bother announcing a trading halt if you are going to resume trading minutes after the announcement is made anyway? It doesn't give us any time to read or understand what has happened and is bound to alienate potential investors. Furthermore, why would you give notice of a conference call within 30 minutes of the conference call commencing? Why not announce something like that on Friday?
2. Why didn’t dr Baldwin or Loveridge participate in the conference? When will we get a chance to be able to ask them questions directly?
About Drug
3. If Presendin has been dropped, what protection against off-label use of generics does Invex have?
Is it only orphan drug designation?
4. Can you contrast the expected PK for Peptron's sustained Exenatide vs. Byetta vs. Daily Presendin.
5. Why is Invex comfortable in proceeding straight to a P3 without repeating the P2 with Peptron's formulation?
6. Will the name "Presendin TM" be dropped or does it now refer to the weekly formulation?
7. What exactly has been licensed in/out and to whom (i.e., by how much have we cut potential profits globally by using Peptron's SR-formulation); for what cost (whether it be financial or otherwise); what are the limitations to each party during and post P3.
Feel free to add more.......
Add to My Watchlist
What is My Watchlist?
